JP2021501776A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501776A5 JP2021501776A5 JP2020524641A JP2020524641A JP2021501776A5 JP 2021501776 A5 JP2021501776 A5 JP 2021501776A5 JP 2020524641 A JP2020524641 A JP 2020524641A JP 2020524641 A JP2020524641 A JP 2020524641A JP 2021501776 A5 JP2021501776 A5 JP 2021501776A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- months
- drug
- drug conjugate
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023179215A JP2024009998A (ja) | 2017-11-02 | 2023-10-18 | 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762580877P | 2017-11-02 | 2017-11-02 | |
| US62/580,877 | 2017-11-02 | ||
| PCT/US2018/058771 WO2019089973A1 (en) | 2017-11-02 | 2018-11-01 | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023179215A Division JP2024009998A (ja) | 2017-11-02 | 2023-10-18 | 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021501776A JP2021501776A (ja) | 2021-01-21 |
| JP2021501776A5 true JP2021501776A5 (https=) | 2021-12-02 |
Family
ID=66332366
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524641A Pending JP2021501776A (ja) | 2017-11-02 | 2018-11-01 | 抗組織因子抗体−薬物コンジュゲートおよびがんの治療におけるその使用 |
| JP2023179215A Pending JP2024009998A (ja) | 2017-11-02 | 2023-10-18 | 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023179215A Pending JP2024009998A (ja) | 2017-11-02 | 2023-10-18 | 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20210177987A1 (https=) |
| EP (1) | EP3703757A4 (https=) |
| JP (2) | JP2021501776A (https=) |
| KR (2) | KR20250044949A (https=) |
| CN (2) | CN119868579A (https=) |
| AU (2) | AU2018358120A1 (https=) |
| BR (1) | BR112020008593A2 (https=) |
| CA (1) | CA3080137A1 (https=) |
| EA (1) | EA202090741A1 (https=) |
| IL (2) | IL274122B2 (https=) |
| MX (1) | MX2020004265A (https=) |
| SG (1) | SG11202003713TA (https=) |
| UA (1) | UA129645C2 (https=) |
| WO (1) | WO2019089973A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020007077A (es) | 2018-01-04 | 2020-10-28 | Iconic Therapeutics Inc | Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados. |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| TW202506732A (zh) | 2018-05-07 | 2025-02-16 | 丹麥商珍美寶股份有限公司 | 使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法 |
| MX2021001058A (es) * | 2018-08-16 | 2021-04-12 | Genmab As | Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de un cancer. |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| CR20220047A (es) * | 2019-07-03 | 2022-06-23 | Zymeworks Inc | Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados |
| TW202132343A (zh) * | 2019-11-07 | 2021-09-01 | 丹麥商珍美寶股份有限公司 | 使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法 |
| EP4171652A1 (en) * | 2020-06-29 | 2023-05-03 | Genmab A/S | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer |
| BR112023018676A2 (pt) | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
| CN119139488A (zh) * | 2023-06-15 | 2024-12-17 | 信达生物制药(苏州)有限公司 | 包含靶向Claudin18.2的抗体-药物偶联物的制剂及其制备方法和用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200800907B (en) * | 2005-07-18 | 2010-04-28 | Bipar Sciences Inc | Treatment of cancer |
| WO2007058935A2 (en) * | 2005-11-14 | 2007-05-24 | Bausch & Lomb Incorporated | Ophthalmic composition for dry eye therapy |
| UA109633C2 (uk) * | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
| BR112012031727B1 (pt) * | 2010-06-15 | 2022-03-29 | Genmab A/S | Conjugado de droga-anticorpo, composição farmacêutica, e, uso do conjugado de droga- anticorpo |
| PL2991683T3 (pl) * | 2013-05-02 | 2020-03-31 | Glykos Finland Oy | Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem |
| PT3347054T (pt) * | 2015-09-11 | 2021-07-15 | Genmab As | Regimes de dosagem para conjugados fármaco-anticorpo anti-tf |
| CN106938051B (zh) * | 2016-08-22 | 2019-10-11 | 复旦大学 | 靶向于组织因子的抗体-药物偶联物 |
-
2018
- 2018-11-01 EA EA202090741A patent/EA202090741A1/ru unknown
- 2018-11-01 UA UAA202002379A patent/UA129645C2/uk unknown
- 2018-11-01 KR KR1020257009636A patent/KR20250044949A/ko active Pending
- 2018-11-01 EP EP18873409.9A patent/EP3703757A4/en active Pending
- 2018-11-01 KR KR1020207015385A patent/KR20200084874A/ko not_active Ceased
- 2018-11-01 US US16/760,373 patent/US20210177987A1/en not_active Abandoned
- 2018-11-01 IL IL274122A patent/IL274122B2/en unknown
- 2018-11-01 IL IL312038A patent/IL312038A/en unknown
- 2018-11-01 CA CA3080137A patent/CA3080137A1/en active Pending
- 2018-11-01 BR BR112020008593-6A patent/BR112020008593A2/pt unknown
- 2018-11-01 MX MX2020004265A patent/MX2020004265A/es unknown
- 2018-11-01 AU AU2018358120A patent/AU2018358120A1/en not_active Abandoned
- 2018-11-01 CN CN202510188791.3A patent/CN119868579A/zh active Pending
- 2018-11-01 JP JP2020524641A patent/JP2021501776A/ja active Pending
- 2018-11-01 WO PCT/US2018/058771 patent/WO2019089973A1/en not_active Ceased
- 2018-11-01 CN CN201880085128.9A patent/CN111655290A/zh active Pending
- 2018-11-01 SG SG11202003713TA patent/SG11202003713TA/en unknown
-
2023
- 2023-08-17 US US18/451,780 patent/US20240252673A1/en not_active Abandoned
- 2023-10-18 JP JP2023179215A patent/JP2024009998A/ja active Pending
-
2024
- 2024-09-11 AU AU2024219631A patent/AU2024219631A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021501776A5 (https=) | ||
| IL312038A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| JP2021518394A5 (https=) | ||
| JP2021515017A5 (https=) | ||
| JP2021523158A5 (https=) | ||
| JP2021523233A5 (https=) | ||
| JP2022513386A5 (https=) | ||
| JP2021534165A5 (https=) | ||
| JP2017110002A5 (https=) | ||
| JP2011507932A5 (https=) | ||
| JP2018527383A5 (https=) | ||
| RU2018111205A (ru) | Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты | |
| TW202440170A (zh) | 抗folr1免疫偶聯物與抗pd-1抗體之組合 | |
| JP2023500697A5 (https=) | ||
| JP2010520290A5 (https=) | ||
| JP2022541591A5 (https=) | ||
| JP2023500888A5 (https=) | ||
| JP2015500822A5 (https=) | ||
| IL278400B2 (en) | Combination of an anti pd-1 antibody and anti tissue factor (tf) antibody drug conjugate for use in the treatment of cancer | |
| JP2022544227A5 (https=) | ||
| CN112218662A (zh) | 抗cd37免疫缀合物给药方案 | |
| JP2025501978A5 (https=) | ||
| TWI870592B (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| JP2024536383A5 (https=) | ||
| CN120437318A (zh) | 抗体药物偶联物和免疫检查点抑制剂的联合应用 |